Effect of rimonabant on weight and cardiometabolic risk factors - Reply

被引：2

作者：

Pi-Sunyer, F. Xavier ^{[1
]}

机构：

[1] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr, New York, NY 10032 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 06期

关键词：

D O I：

10.1001/jama.296.6.650

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：650 / 651

页数：2

共 6 条

[1]

[Anonymous], 2000, The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults

[2] Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents [J].

Griebel, G ;

Stemmelin, J ;

Scatton, B .

BIOLOGICAL PSYCHIATRY, 2005, 57 (03) :261-267

[3] Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? [J].

Hill, MN ;

Gorzalka, BB .

BEHAVIOURAL PHARMACOLOGY, 2005, 16 (5-6) :333-352

[4] Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice [J].

Shearman, LP ;

Rosko, KM ;

Fleischer, R ;

Wang, J ;

Xu, S ;

Tong, XS ;

Rocha, BA .

BEHAVIOURAL PHARMACOLOGY, 2003, 14 (08) :573-582

[5] The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions [J].

Tzavara, ET ;

Davis, RJ ;

Perry, KW ;

Li, X ;

Salhoff, C ;

Bymaster, FP ;

Witkin, JM ;

Nomikos, GG .

BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (04) :544-553

[6] A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders [J].

Witkin, JM ;

Tzavara, ET ;

Davis, RJ ;

Li, X ;

Nomikos, GG .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (12) :609-617

← 1 →